Trial Profile
A PHASE 3B MULTICENTER, DOUBLE-BLIND, RANDOMIZED WITHDRAWAL EFFICACY AND SAFETY STUDY OF PREGABALIN IN THE TREATMENT OF PATIENTS WITH INADEQUATELY TREATED PAINFUL DIABETIC PERIPHERAL NEUROPATHY
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Jan 2021
Price :
$35
*
At a glance
- Drugs Pregabalin (Primary)
- Indications Neuropathic pain
- Focus Therapeutic Use
- Sponsors Pfizer
- 05 May 2012 Primary endpoint 'Pain-measures' has not been met.
- 04 Apr 2012 Actual end date (Jan 2012) added as reported by ClinicalTrials.gov.
- 04 Apr 2012 Actual patients number is 636 as reported by ClinicalTrials.gov.